


Revolutionizing the Science of Antimicrobial Protection



**The first Central Venous Catheter
with an integrated antimicrobial material**

Edwards Vantex Catheter with Oligon Agent




Edwards
LIFESCIENCES

The Vantex Catheter with Oligon Agent: Providing broad

Revolutionary antimicrobial material

- Extruded from polyurethane, combined with the natural elements silver, carbon and platinum
- Releases silver ions from the device material, which kills colonizing bacteria on both inner and outer catheter surfaces
- Integral to the polymer of the catheter, the Oligon agent is not a coating that could wash away



Cross section of catheter shows active release of silver ions from all catheter surfaces into the surrounding environment, providing antimicrobial protection

Superior Biocompatibility¹

Toxicity Response of Mice Exposed to CVC Extracts During the USP Mouse Systemic Test (extracted 70°C/24 hours)

Vantex Central Venous Catheter with Oligon antimicrobial agent



Chlorhexidine and silver sulfadiazine coated




Choose superior biocompatibility. Small concentrations of silver have shown no detrimental effects on normal mammalian cells



-spectrum antimicrobial[†] protection that won't wash off.

Reduce the risk of vessel perforation using the soft tip with the Oligon agent



Clinical Results

- Significantly reduced the catheter colonization rate in a prospective randomized trial at ten institutions versus a standard catheter²
- Reduced catheter-related infection rates by 48% in a second study when substituted for an alternative antimicrobial catheter³


Include traditional Edwards Lifesciences CVC benefits

- Allow easy CVC insertion with single-handed guidewire insertion device
- Infuse fluids up to 77% faster than with competing CVCs, due to optimized lumen and backform design¹
- Minimize needlestick risks with Interlink injection caps
- Optional heparin coating available

Provide broad-spectrum antimicrobial protection

- Protects against gram-negative and gram-positive bacteria — as well as fungi and resistant micro-organism strains — with the Oligon agent, silver
- Destroys bacteria, resulting in ≥ 3 log reduction of microorganisms within 48 hours

Minimum Inhibitory Concentrations⁴ (micrograms/milliliter)



A family of venous access technologies

Edwards offers other members of the access family, including introducers and central venous catheters, as well as a full line of Edwards Swan-Ganz Catheters, disposable pressure transducers and a blood management protection system.

For additional information, call your Edwards representative at (800) 424-3278, or visit www.edwards.com for details.

The activity of the antimicrobial agent is localized at the catheter surfaces and is not intended for treatment of systemic infections. *In vitro* testing demonstrated that the Oligon agent provided broad spectrum effectiveness (≥ 3 log reduction from initial concentration within 48 hours) against the organisms tested: *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Klebsiella pneumoniae*, *Enterococcus faecalis*, *Candida albicans*, *Escherichia coli*, *Serratia marcescens*, *Acinetobacter calcoaceticus*, *Corynebacterium diphtheriae*, *Enterobacter aerogenes*, *GMRSa*, *Pseudomonas aeruginosa*, *Candida glabrata* and *VRE (Enterococcus faecium)*.

Edwards Lifesciences, Edwards, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. Swan-Ganz and Vantex are trademarks of Edwards Lifesciences Corporation and are registered in the U.S. Patent and Trademark Office. Interlink is a trademark of Baxter International Inc., registered in the U.S. Patent and Trademark Office. Oligon is a trademark of Implemed, Inc.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

© 2004 Edwards Lifesciences LLC.
All rights reserved. AR00486

References

1. Data on file. Edwards Lifesciences LLC.
2. Ranucci M, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. *Crit Care Med* 2003;31(1):52-59.
3. Garcia R, et al. Three years experience in implementing HICPAC recommendations for the reduction of central venous catheter-related bloodstream infections. Poster Presentation at National APIC Meeting, June 2003.
4. Berger TJ, et al. Electrically generated silver ions: quantitative effects on bacterial and mammalian cells. *Antimicrobial Agents and Chemotherapy* 1976;9(2):357-358.



Edwards Lifesciences

**ASIA PACIFIC - Edwards Lifesciences India Pvt. Ltd., E, F - 201 204, Remi Bizcourt,
Shah Indl. Estate, Plot No: 9, Veera Desai Road, Andheri (West), Mumbai - 400 053, India
Phone: +91 22 5693 5701 - 04 • Fax: +91 22 5693 5705 • www.edwards.com**

Edwards Lifesciences LLC · One Edwards Way · Irvine, CA 92614 USA · 949.250.2500 · 800.424.3278

Edwards Lifesciences (Canada) Inc. · 1290 Central Pkwy West, Suite 300 · Mississauga, Ontario · Canada L5C 4R3 · Phone 905.566.4220 · 800.268.3993

Edwards Lifesciences S.A. · Ch. du Glapin 6 · 1162 Saint-Prex · Switzerland · Phone 41.21.823.4300

Edwards Lifesciences Japan · 2-8 Rokubancho · Chiyoda-ku, Tokyo 100-0085 · Japan · Phone 81.3.5213.5700